In Vitro Activity of Vinorelbine on Human Leukemia Cells

Authors: Landini, I.; Bartolozzi, B.; Banchelli, I.; Innocenti, A. Degli; Nocentini, O.; Bernabei, P.A.

Source: Journal of Chemotherapy, Volume 13, Number 3, 2001 , pp. 309-315(7)

Buy & download fulltext article:

Price: $25.00 plus tax (Refund Policy)

Abstract:

Vinorelbine (VNR) is a semi-synthetic Vinca rosea alkaloid that has been employed both as a single agent and in combination, and has shown significant antitumor activity. As little is known about VNR activity on human leukemia, we studied its In Vitro cytotoxic effect on human leukemia cell lines (FLG 29.1, HL60, K562, Balm 4, CEM and Daudi) and on fresh leukemia cells from 28 patients: 2 acute myeloid leukemia (AML); 3 chronic myeloid leukemia in blas-tic phase (CML-BP); 5 acute lymphoblastic leukemia (ALL); 18 B-chronic lymphatic leukemia (B-CLL), employing the colorimetric INT assay and determining the IC₅₀.

We observed that VNR exerts its cytotoxic activity on leukemic cell lines in a dose-dependent fashion. The lymphoid cell lines appear more sensitive than the myeloid ones to the VNR-dependent growth inhibition.

A similar pattern was noticed for leukemia cells in primary cultures. VNR is not effective on CML-BP cells, shows variable activity on the AML and ALL cells and is very effective against B-CLL cells. VNR inhibited the growth of fresh B-CLL cells from 15 of 18 patients, the IC₅₀ doses ranging from 4 ng/ml to 83 μg/ml (doses coinciding with the plasma levels obtained in clinics). These observations strongly suggest that VNR could be useful in clinics for the treatment of B-CLL.

Document Type: Research Article

Publication date: 2001-01-01

More about this publication?